Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

E-Z-Em to market Pharmacyclics' Gadolite:

This article was originally published in Clinica

Executive Summary

E-Z-Em has obtained exclusive North American marketing rights to Pharmacyclics' MRI oral contrast agent, Gadolite. US FDA approval for use of the agent in abdominal and pelvic imaging will be sought by Pharmacyclics this year. Phase III trials were completed earlier this year (see Clinica No 645, p 22). E-Z-Em, which has the option to negotiate additional marketing rights, will collaborate on development of Gadolite and other products using Pharmacyclics' technology. The two companies will share profits on net sales of Gadolite.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093012

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel